(Q51317229)

3 April 2018

title

Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study. (English)

1 reference

3 April 2018

0 references

1

1 reference

3 April 2018

author name string

R Camisasca

series ordinal

2

1 reference

3 April 2018

C Wilson

series ordinal

3

1 reference

3 April 2018

P Fleck

series ordinal

4

1 reference

3 April 2018

publication date

25 September 2014

1 reference

3 April 2018

Diabetes, Obesity and Metabolism

published in

1 reference

3 April 2018

volume

16

1 reference

3 April 2018

issue

12

1 reference

3 April 2018

page(s)

1239-1246

1 reference

3 April 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

cites work

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies

21 January 2018

1 reference

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia

21 January 2018

1 reference

Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial

21 January 2018

1 reference

Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus

21 January 2018

1 reference

Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.

21 January 2018

1 reference

Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes

21 January 2018

1 reference

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12377

1 reference

3 April 2018

PubMed ID

25132212

1 reference

3 April 2018